Takeda announced TAKHZYRO® (lanadelumab-flyo) injection single-dose prefilled syringe is now available in the U.S. to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older. HAE is a rare genetic disease that results in recurrent attacks of edema (swelling) in various parts of the body, which can be burdensome, debilitating and potentially life-threatening. Approved by the U.S. Food and Drug Administration on February 8, 2022, the TAKHZYRO prefilled syringe is ready to use and requires fewer preparation steps than the single-dose vial, enhancing the treatment administration experience.

With a proven efficacy and safety profile and real-world experience, TAKHZYRO has been available in the U.S. since 2018 helping to prevent HAE attacks in patients 12 and older. TAKHZYRO is supported by a robust clinical development program, which includes one of the largest prevention studies in HAE with the longest active treatment duration, HELP (Hereditary Angioedema Long-term Prophylaxis) Study™. Results from the HELP Study Open-Label Extension (OLE) found consistent safety and efficacy results with TAKHZYRO in a treatment period of up to 132 weeks.